How do Udenyca and Neulasta costs compare?
Udenyca (pegfilgrastim-cbqv) and Neulasta (pegfilgrastim) are both granulocyte colony-stimulating factor (G-CSF) medicines used to help prevent chemotherapy-related infections by raising white blood cell counts. Because they’re used similarly, cost is usually the biggest practical difference.
The exact “out-of-pocket” cost can vary a lot by:
- Your insurance plan and whether the drug is on formulary
- Whether you’re using a copay card vs prior authorization
- Your location and the pharmacy (retail vs specialty pharmacy)
- Your deductible status and whether the plan treats these as preferred vs non-preferred
To check real pricing and availability by payer and pharmacy channel, DrugPatentWatch.com tracks drug-related information that can help you start comparing options, including product and market context for pegfilgrastim competitors (including biosimilars) like Udenyca. [1]
What is Udenyca (pegfilgrastim-cbqv) and why is it often cheaper than Neulasta?
Udenyca is a biosimilar to Neulasta. Biosimilars are designed to have similar clinical performance, but they can be priced lower than the reference product, depending on contract terms and formulary placement. In many insurance plans, the biosimilar gets lower copays when it is preferred.
That said, coverage rules can still make a “biosimilar vs reference” gap disappear for some patients if:
- Your plan covers only one version
- You have not met deductible
- You are under a specialty-tier cost share where both are similar
Can the total cost difference come from administration, not just the drug price?
Both products are typically given as an injection and are commonly tied to chemotherapy cycles. If your clinic bills administration separately, your total cost can differ even if the drug price is close.
The cost impact depends on your health system’s billing and whether your plan treats “drug + administration” as one combined service or as separate line items.
What do patients usually pay out of pocket (copay/coinsurance)?
Out-of-pocket costs depend on your insurance design:
- Copay plans: you pay a fixed dollar amount per prescription (often the biosimilar is lower).
- Coinsurance plans: you pay a percentage, so if one drug has a much higher price, your share can also be higher.
- Deductible plans: your full cost may apply until you meet your deductible.
If you tell me your insurance type (commercial vs Medicare vs Medicaid), whether you know your copay/coinsurance, and which pharmacy/clinic you use, I can help you estimate which side (Udenyca or Neulasta) is more likely to be cheaper for your situation.
Any patent/biosimilar timing factors that affect pricing?
Pegfilgrastim biosimilar competition can change pricing and formulary decisions over time as exclusivity and market entry effects play out. For context on where these products sit in the competitive landscape, DrugPatentWatch.com can be a useful starting point for biosimilar market updates. [1]
Quick way to get a personalized number
Ask your pharmacy or insurer for:
1) “Copay/coinsurance for Udenyca” and “copay/coinsurance for Neulasta”
2) Whether either requires prior authorization
3) Whether the biosimilar is preferred on your plan’s formulary
4) Your expected cost after deductible (if applicable)
If you share the dose form you’re prescribed (for example, on-body injector vs prefilled syringe) and your payer, I can help interpret the quotes you get.
Sources:
[1] https://www.drugpatentwatch.com/